The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV).
 
Aniket Bankar
Consulting or Advisory Role - Protagonist Therapeutics
 
Kristen Pettit
Consulting or Advisory Role - Abbvie; Incyte; PharmaEssentia; Protagonist Therapeutics; Sierra Oncology
Research Funding - Abbvie (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Imago Pharma (Inst); Kura Oncology (Inst); Merck (Inst); Protagonist Therapeutics (Inst)
 
Joseph Shatzel
Consulting or Advisory Role - Aronora Inc.
 
Abdulraheem Yacoub
Consulting or Advisory Role - Abbvie; Acceleron Pharma; Apellis Pharmaceuticals; Bristol-Myers Squibb; CTI; Gilead Sciences; Incyte; Notable Labs; Novartis; Pfizer; PharmaEssentia; SERVIER
 
Naveen Pemmaraju
Employment - MD Anderson Cancer Center
Leadership - ASCO; ASH
Consulting or Advisory Role - Abbvie; Aplastic Anemia and MDS International Foundation; Aptitude Health; Astellas Pharma; Blueprint Medicines; Bristol Myers Squibb; CancerNet; CareDx; Celgene; Cimeio Therapeutics; Clearview Healthcare Partners; CTI BioPharma Corp; Curio Science; Dava Oncology; EUSA Pharma; Harborside Press; Imedex; Immunogen; Intellisphere; Intellisphere; Magdalen Medical Publishing; Medscape; Menarini Group; Neopharm; Novartis; OncLive; Pacylex; Patient Power; Peerview; Pharmaessentia; Physicans' Education Resource
Research Funding - US DOD (Inst)
Other Relationship - Karger Publishers
(OPTIONAL) Uncompensated Relationships - Dan's House of Hope; Oncology Times
 
Harinder Gill
Honoraria - Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Otsuka; PharmaEssentia
Travel, Accommodations, Expenses - MSD; Novartis; Pfizer; PharmaEssentia
Other Relationship - Imago Biosciences; PharmaEssentia
 
Antonin Hlusi
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Novo Nordisk; Octapharm; SOBI
 
Alessandro Lucchesi
Consulting or Advisory Role - Amgen; Grifols; MorphoSys; Novartis; Protagonist Therapeutics; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Grifols; Incyte; Novartis; Pfizer; Sanofi; SOBI
 
Samah Alimam
Consulting or Advisory Role - Protagonist Therapeutics
 
Jiří Mayer
Research Funding - BeiGene; Protagonist Therapeutics; Roche
 
Francesca Palandri
Honoraria - Abbvie; Amgen; AOP Orphan Pharmaceuticals; Celgene; Celgene/Bristol-Myers Squibb; CTI; GlaxoSmithKline; Grifols; Karyopharm Therapeutics; MorphoSys; Novartis; Sierra Oncology; SOBI
Consulting or Advisory Role - Abbvie; Amgen; AOP Orphan Pharmaceuticals; Celgene; Celgene/Bristol-Myers Squibb; CTI; GlaxoSmithKline; Grifols; Karyopharm Therapeutics; MorphoSys; Novartis; Sierra Oncology; SOBI
 
Daniel Sasca
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences
 
Katharina Modelska
Employment - Protagonist Therapeutics
Leadership - Protagonist Therapeutics
Stock and Other Ownership Interests - Protagonist Therapeutics
 
Suneel K Gupta
Employment - Protagonist Therapeutics
Stock and Other Ownership Interests - Protagonist Therapeutics (I)
 
Ifode Ajari
Employment - Protagonist Therapeutics
Stock and Other Ownership Interests - Protagonist Therapeutics
 
Sarita Khanna
Employment - Protagonist Therapeutics
Leadership - Protagonist Therapeutics
Stock and Other Ownership Interests - Protagonist Therapeutics
 
Arturo Molina
Employment - Protagonist Therapeutics
Leadership - Protagonist Therapeutics
Stock and Other Ownership Interests - Protagonist Therapeutics
 
Andrew Tucker Kuykendall
Honoraria - Abbvie/Genentech; Blueprint Medicines; BMS; GlaxoSmithKline; Imago Pharma; Incyte; MorphoSys; Pharmaessentia; SOBI
Consulting or Advisory Role - GlaxoSmithKline; GlaxoSmithKline; Karyopharm Therapeutics; MorphoSys; Protagonist Therapeutics
Research Funding - Blueprint Medicines (Inst); Bristol-Myers Squibb/Celgene (Inst); Geron (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); MorphoSys (Inst); Novartis (Inst); Protagonist Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; GlaxoSmithKline; Pharmaessentia